<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343313</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-0001</org_study_id>
    <nct_id>NCT04343313</nct_id>
  </id_info>
  <brief_title>The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study</brief_title>
  <official_title>Evaluation of the Safety and Performance of the Half Moon Transcatheter Mitral Valve Repair System in High Risk Patients With Severe, Symptomatic Mitral Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Half Moon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Half Moon Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study&#xD;
      (EFS) to evaluate the safety and performance of the Half Moon TMVr System in patients with&#xD;
      severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 Days</time_frame>
    <description>Evaluation of the nature, severity and frequency of complications associated with the delivery and/or implantation of the device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Placement</measure>
    <time_frame>30 Days (+ annually through 5 years)</time_frame>
    <description>Assessment of the ability to accurately deliver and place the implant within the native anatomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Performance</measure>
    <time_frame>30 Days (+ annually through 5 years)</time_frame>
    <description>The degree of improvement of MR grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Improvement</measure>
    <time_frame>30 Days (+ annually through 5 years)</time_frame>
    <description>The degree of improvement of MR symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Durability</measure>
    <time_frame>30 Days (+ annually through 5 years)</time_frame>
    <description>The durability of TMVr function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Half Moon TMVr System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Half Moon TMVr System</intervention_name>
    <description>The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.</description>
    <arm_group_label>Half Moon TMVr System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Moderately severe or severe mitral regurgitation (MR Grade ≥ 3+)&#xD;
&#xD;
          2. Symptomatic mitral regurgitation (NYHA Class II-IV), despite guideline-directed&#xD;
             medical therapy (GDMT) determined by the local multidisciplinary heart team&#xD;
&#xD;
          3. Deemed, by the local multidisciplinary heart team, to be at high risk for mitral valve&#xD;
             surgery and not appropriate for commercially approved transcatheter mitral valve&#xD;
             therapies&#xD;
&#xD;
          4. Age ≥ 21&#xD;
&#xD;
          5. Native mitral valve geometry and size compatible with the Half Moon TMVr implant&#xD;
&#xD;
          6. Anatomy suitable for transfemoral transseptal access with the Half Moon TMVr System&#xD;
&#xD;
          7. Willing to sign Informed Consent for participation in the study and return for all&#xD;
             required post-procedure follow-up visits&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior transseptal intervention with occlusion device currently implanted&#xD;
&#xD;
          2. Implanted with venous stents (iliac and femoral) including inferior vena cava (IVC)&#xD;
             filter or congenital abnormalities of the IVC that would preclude ability for&#xD;
             transfemoral access with the delivery system&#xD;
&#xD;
          3. Evidence of intracardiac, inferior vena cava, or femoral venous mass, thrombus, or&#xD;
             vegetation&#xD;
&#xD;
          4. Prohibitive mitral annular or leaflet calcification&#xD;
&#xD;
          5. Diseased mitral anterior leaflet such as flail or prolapse&#xD;
&#xD;
          6. Left ventricular ejection fraction (LVEF) &lt; 25%, or LVEF 25-30% in the presence of&#xD;
             left ventricular end diastolic volume index (LVEDVi) &gt;120mL/m2 as measured by resting&#xD;
             echocardiogram within 30 days of the Index Procedure&#xD;
&#xD;
          7. Left ventricular end diastolic diameter (LVEDD) &gt; 75mm&#xD;
&#xD;
          8. Pulmonary hypertension with resting pulmonary artery systolic pressures ≥ 2/3 systemic&#xD;
             systolic pressure&#xD;
&#xD;
          9. Right-sided congestive heart failure with echocardiographic evidence of severe right&#xD;
             ventricular dysfunction&#xD;
&#xD;
         10. Severe tricuspid regurgitation&#xD;
&#xD;
         11. Prior mitral valve surgery or endovascular procedure, or need for other valve&#xD;
             surgery/procedure&#xD;
&#xD;
         12. Any endovascular therapeutic interventional or surgical procedure performed within 30&#xD;
             days prior to enrollment&#xD;
&#xD;
         13. Prior stroke, TIA, or myocardial infarction within 90 days&#xD;
&#xD;
         14. Need for coronary revascularization&#xD;
&#xD;
         15. Severe symptomatic carotid artery stenosis&#xD;
&#xD;
         16. Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by Forced Expiratory&#xD;
             Volume (FEV1) &lt; 750cc&#xD;
&#xD;
         17. Need for emergent surgery&#xD;
&#xD;
         18. Endocarditis within 6 months&#xD;
&#xD;
         19. Subject is unwilling or unable to adhere to the protocol recommended anticoagulation&#xD;
             treatment&#xD;
&#xD;
         20. GI bleeding within 6 months&#xD;
&#xD;
         21. History of bleeding diathesis or coagulopathy or patient will refuse blood transfusion&#xD;
&#xD;
         22. Hemodynamic instability requiring dependency on either inotropic agents or mechanical&#xD;
             circulatory support&#xD;
&#xD;
         23. Platelet count of &lt;75,000 cells/mm3&#xD;
&#xD;
         24. Renal insufficiency (Creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
         25. Active infections requiring current antibiotic therapy (if temporary illness, patients&#xD;
             may enroll 2 weeks after discontinuation of antibiotics)&#xD;
&#xD;
         26. Contraindication to transesophageal echocardiography (TEE)&#xD;
&#xD;
         27. Known hypersensitivity or contraindication to study or procedure medications/contrast&#xD;
             which cannot be adequately managed medically&#xD;
&#xD;
         28. Pregnant, nursing or planning to be pregnant. (Female participants of childbearing&#xD;
             potential must have a negative pregnancy test prior to enrollment)&#xD;
&#xD;
         29. Currently participating in an investigational drug or another device study that has&#xD;
             not yet reached its primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Craig Straley</last_name>
    <phone>4153109197</phone>
    <email>craigstraley.halfmoon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romil Rambhia</last_name>
    <email>rrambhia@thefoundry.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center/NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susheel Kodali, MD</last_name>
      <email>sk2427@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kate Dalton</last_name>
      <email>keb2114@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susheel Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

